insights_auto
Outlook: 26.7% bullish·0.0% bearish
Go to analysischevron_right
U2TH34:BVMF
United Therapeutics Corp Bdr
R$136.89
0.00%
(0.00) 1D
Oct 7, 10:59:10 AM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for U2TH34...
Mkt. cap
23.30B
Avg. vol.
276.00
Volume
0.00
52-wk high
R$155.07
52-wk low
R$113.63
Shares outstanding
42.89M
No. of employees
1K
Mkt. cap
23.30B
Avg. vol.
276.00
Volume
0.00
52-wk high
R$155.07
52-wk low
R$113.63
Shares outstanding
42.89M
No. of employees
1K
News stories
From web sources and news partners
Profile
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire. Wikipedia
About United Therapeutics Corp Bdr
CEO-
Employees1.4K
Founded1996
HeadquartersSilver Spring, Maryland, United States
SectorBiotechnology
Websiteunither.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 799.50M | 790.20M | 781.50M | 783.30M |
Cost of goods sold | 100.90M | 103.40M | 133.40M | 99.50M |
Cost of revenue | 100.90M | 103.40M | 133.40M | 99.50M |
Research and development expenses | 127.50M | 139.50M | 138.20M | 146.30M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 181.80M | 189.90M | 184.10M | 206.70M |
Operating expense | 309.30M | 329.40M | 322.30M | 353.00M |
Total operating expenses | 410.20M | 432.80M | 455.70M | 452.50M |
Operating income | 389.30M | 357.40M | 325.80M | 330.80M |
Other non operating income | 300.00K | 800.00K | 15.30M | -100.00K |
EBT including unusual items | 438.00M | 444.00M | 318.30M | 372.70M |
EBT excluding unusual items | 433.00M | 398.30M | 379.90M | 359.30M |
Income tax expense | 99.30M | 79.70M | 43.40M | 39.70M |
Effective tax rate | 22.67% | 17.95% | 13.63% | 10.65% |
Other operating expenses | - | - | - | - |
Net income | 338.70M | 364.30M | 274.90M | 333.00M |
Net profit margin | 42.36% | 46.10% | 35.18% | 42.51% |
Earnings per share | 7.16 | 7.70 | 5.82 | 7.27 |
Interest and investment income | 46.40M | 43.20M | 41.80M | 31.50M |
Interest expense | -3.00M | -3.10M | -3.00M | -2.90M |
Net interest expenses | 43.40M | 40.10M | 38.80M | 28.60M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 411.20M | 380.20M | 348.40M | 355.00M |
Gain or loss from assets sale | - | - | - | - |